A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus

NCT03962010 · Unknown status

Last updated 2026-05-28

This clinical trial tested the safety and effects of the experimental drug GX-G6 over 12 weeks in adults with uncontrolled type 2 diabetes.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 78 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2019-06 · est. completion 2022-07

What this study is testing ClinicalTrials.gov NCT03962010 ↗

Description as written by the study sponsor.

GX-G6-002 is a Phase 2, 12-week, randomized, parallel group, multi-centre, double blind, placebo-controlled and an open-label active comparator study.

Treatments tested

GX-G6 Drug

long acting anti-diabetic drug
Control Drug

Control

Main thing measured	Change in HbA1c
Sponsor	Genexine, Inc.
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03962010 ↗